The most frequently reported side effects across all tirzepatide clinical trials are gastrointestinal, including nausea (reported in 12-29% of participants depending on dose), diarrhea (12-16%), constipation , and decreased appetite
NAD+, on the other hand, is just NAD once its become oxidized
Glucagon Inhibition: It reduces the secretion of glucagon, a hormone that raises blood sugar levels, thus preventing excessive glucose production by the liver
Preclinical studies suggest GLP-1 agonists may reduce synovial macrophage infiltration and decrease production of matrix metalloproteinasesenzymes responsible for cartilage degradation in RA
Overall, they found that individuals using GLP-1s were 10% less likely to visit the emergency room, 14% less likely to be hospitalized, and around 13% less likely to need a nerve block procedure or receive a triptan prescription than those taking topiramate
Safety and effectiveness of the intragastric balloon for obesity